Founding Partner
Biotech patent prosecution is the legal process of getting a patent application examined and granted by the USPTO. It starts with claim drafting and runs through every Office Action, examiner interview, and continuation decision. The companies that build the strongest biotech patent portfolios are the ones that treat prosecution as a long game.
Filing a biotech patent application is not the hard part. Getting it through prosecution with claims broad enough to matter is. That’s because biotech patent prosecution involves scientific and legal challenges that do not exist in the same form in any other field.
Richard Gearhart, founding partner of Gearhart Law, is a trained chemist and former senior in-house IP leader in the life sciences industry. With nearly 30 years of helping pharmaceutical, biotechnology, medical device, diagnostics, and health-technology companies build patent portfolios that hold up, he is the right
This post covers the prosecution strategies that make the difference between a patent that protects your business and one that a competitor can design around.
Claim Drafting Strategy: Where Biotech Prosecution Is Won or Lost
The claims you file determine the scope of your protection. Getting that scope right means balancing breadth against what the science can actually support at the time of filing.
Genus and Species Claims
Most biotech patent strategies involve a hierarchy of claims:
- Genus claims cover a broad class of compounds, methods, or compositions
- Species claims protect specific embodiments within that class as fallback positions
The goal is to hold the genus as long as possible. The risk is overreach. A genus claim not fully supported by the specification will face a written description rejection that is hard to overcome without narrowing. It’s best to file with a specification as comprehensive as the science allows at the time of filing.
Functional Claiming
Functional claims describe what a compound does rather than what it is. Examiners treat these with particular scrutiny.
A functional limitation covering any compound achieving a result, without structural definition, may face an enablement rejection. The stronger your specification, with examples, data, and mechanistic explanation, the better your functional claims will hold up.
Biological Deposit Requirements
When a biotech invention involves biological material that cannot be fully described in words and is not publicly accessible, such as a specific cell line, microorganism, or novel biological sequence, the United States Patent and Trademark Office (USPTO) may require a biological deposit with a recognized depository authority.
Failing to make a required deposit, or making it too late, can result in a rejection that is very difficult to fix after filing. Deposit requirements should be identified before the application is filed, not after an Office Action arrives.
Responding to Biotech Office Actions: What Works and What Does Not
Biotech applications receive more Office Actions on average than most other technology areas. Here are the four rejections that require the most strategic thought.
Patentable Subject Matter
An examiner who concludes your claims are directed to a natural phenomenon or law of nature will reject them regardless of how novel the science is.
The most effective responses demonstrate that your claims are directed to a specific technical application of a biological principle, not the principle itself. This means showing meaningful human intervention that produces a concrete, specific result, instead of a mere observation or correlation. For a detailed breakdown of how these rejections are evaluated, see our post on navigating patent eligibility in biotechnology post-Alice.
Written Description and Enablement
These two rejections are closely related but legally distinct. Both are common in biotech and often appear together in the same Office Action.
- Written description: The examiner believes the specification does not show you had the full scope of what you are claiming at the time of filing. Common when a broad genus claim covers many embodiments, but the specification only provides examples for a narrow subset.
- Enablement: The examiner believes a person skilled in the field could not make and use the full scope of the claimed invention without undue experimentation. Common when functional claims cover a broad class of compounds, but the specification does not give enough guidance on how to make every member of that class.
How to respond: Combine claim amendment with a scientific argument, supported by expert declarations where possible. Narrowing to a scope the specification actually supports, while arguing the original scope was warranted, gives you the best chance of keeping meaningful breadth.
Double Patenting
Life sciences companies building portfolios around a single platform often file multiple related applications over time. This creates double patenting risk, where two applications owned by the same entity claim overlapping subject matter. There are two types:
- Statutory double patenting arises when two claims are identical.
- Non-statutory obviousness-type double patenting arises when two claims are not identical, but one would have been obvious in light of the other. The second is far more common in biotech portfolios.
The standard fix: You can file a terminal disclaimer, which ties the expiration of the later patent to the earlier one. This resolves the rejection but shortens the effective life of the later patent. Anticipate double patenting issues when structuring continuation applications so terminal disclaimers do not unnecessarily erode your portfolio term.
If your biotech application is in prosecution and you are facing Office Actions or building a continuation strategy, the patent attorneys at Gearhart Law can help. Reach out for a free half-hour consultation.
Using Examiner Interviews to Move Biotech Applications Forward
An examiner interview is a direct conversation between your attorney and the USPTO examiner assigned to your application. Interviews work especially well in biotech because Section 101 rejections often stem from how the invention is framed rather than a flaw in the underlying science.
An attorney who understands the biology can correct that framing in a conversation far more efficiently than in writing. The same is true for written description and enablement rejections, which frequently involve a misunderstanding of the technical subject matter that is easier to address directly than on paper.
When to Request an Examiner Interview
Request one after you have received a rejection and identified a clear path to resolution but before you commit to a formal written response that locks you into a position.
Before the Interview
Your attorney should file a pre-interview submission outlining the proposed amendments or arguments so the examiner can review them in advance. This makes the conversation more productive and signals that your attorney is prepared and serious about resolving the rejection.
Build a Biotech Patent Portfolio That Goes the Distance With Gearhart Law
The decisions made during prosecution, including how claims are drafted, how Office Actions are responded to, when examiner interviews are requested, and how continuations are structured, determine not just whether a patent issues, but whether it is worth anything when it does.
Gearhart Law works with life sciences companies throughout New Jersey and beyond to build biotech patent portfolios that hold up. Our team brings both scientific training and decades of prosecution experience to every application. Leave your details, and we will be in touch, or call 908.273.0700 for a free half-hour consultation.
Frequently Asked Questions About Biotech Patent Prosecution
1. What is biotech patent prosecution?
Biotech patent prosecution is the process of working with the USPTO to get a patent application examined and granted. It includes responding to Office Actions, amending claims, conducting examiner interviews, and making strategic decisions about how to build and extend a patent portfolio.
2. What is a written description rejection?
A written description rejection means the examiner does not believe your patent application shows you actually had the full invention worked out when you filed. In biotech, this often happens when your claims cover a wide range of compounds or methods, but your application only includes examples for a small portion of them.
3. How is an enablement rejection different from a written description rejection?
A written description rejection is about whether you had the invention. An enablement rejection is about whether you taught others how to practice it. Enablement means the examiner believes a person skilled in the field could not make and use the full scope of the claimed invention without undue experimentation. Both are common in biotech and often appear together in the same Office Action.
4. How do you respond to a Section 101 rejection in biotech?
The strongest responses show that your invention does something specific and useful with a biological discovery, rather than just claiming the discovery itself. In other words, you are not patenting a fact about nature, but rather a specific method or process that puts that fact to work in a defined, practical way.
5. What is a continuation application?
A continuation application lets you file for additional patent protection based on the same original application, as long as that application is still open at the USPTO. In biotech, this matters because a single patent rarely covers everything your platform technology does. Continuations let you broaden your coverage over time, respond to how competitors are trying to work around your patents, and keep your IP protection growing as your research advances.
6. What is a terminal disclaimer?
A terminal disclaimer is a document you file to resolve a specific type of rejection that arises when two of your own patents are too similar to each other. It works by linking the expiration date of the newer patent to the older one, so they both expire at the same time. This fixes the rejection but shortens the life of the newer patent.
7. Is an examiner interview worth requesting?
Yes, in most cases. An examiner interview lets you understand the examiner’s concerns directly and propose a resolution before committing to a formal written response. In biotech, where Section 101, written description, and enablement rejections involve complex scientific arguments, an attorney who understands the science can move an application forward faster than written responses alone. Contact Gearhart Law to discuss your prosecution strategy.
8. How long does biotech patent prosecution take?
From filing to a first Office Action, the wait is often 18 to 24 months or more. Total prosecution time from filing to grant can range from three to five years depending on the complexity of the application and the number of rounds of examination. Filing a provisional patent application first locks in your priority date while you finalize the formal application, which is an important move in fields where competitors are active.